Biote announces $60 million agreement to repurchase 8.3 million shares and cancel approximately 4.0 million earnout shares

Irving, texas--(business wire)--biote corp. (nasdaq: btmd) (“biote” or the “company”), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced it has signed a binding term sheet with marci m. donovitz, stockholder of biote, to resolve litigation (“donovitz litigation”). for $60 million in the aggregate, biote will repurchase all of the approximately 8.3 million of the paired interests and/or class.
BTMD Ratings Summary
BTMD Quant Ranking